Rise and shine, everyone, the middle of the week is here. You made it this far, so why not forge ahead, yes? Despite a wintry chill, we are doing our best with the help of some cups of stimulation — we are quaffing hazelnut this morning — and invite you to join us. After all, a prescription is not required, so go ahead and indulge. Meanwhile, we have assembled the latest menu of tidbits to get you started on another busy day. Hope all goes well and you conquer the world. Cheers …

Takeda Pharmaceutical (TKPYY) shareholders voted in favor of a deal to buy Shire (SHPG), crushing an opposition campaign that sought to derail the biggest overseas acquisition by a Japanese company, the Wall Street Journal tells us. At least 88 percent of votes cast were in favor, dealing a blow to a group of longtime shareholders who had lobbied to block the cash-and-stock merger, valued at about $58 billion today. The dissidents argued Takeda (TAK) was overpaying for Shire and piling on too much debt to do so.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy